EA201391056A1 - Гетероарильные соединения в качестве лигандов 5-htрецептора - Google Patents

Гетероарильные соединения в качестве лигандов 5-htрецептора

Info

Publication number
EA201391056A1
EA201391056A1 EA201391056A EA201391056A EA201391056A1 EA 201391056 A1 EA201391056 A1 EA 201391056A1 EA 201391056 A EA201391056 A EA 201391056A EA 201391056 A EA201391056 A EA 201391056A EA 201391056 A1 EA201391056 A1 EA 201391056A1
Authority
EA
Eurasian Patent Office
Prior art keywords
htreceptor
ligands
heteroaryl compounds
compounds
formula
Prior art date
Application number
EA201391056A
Other languages
English (en)
Other versions
EA022374B1 (ru
Inventor
Рамакришна Нироджи
Абдул Рашид Мохаммед
Суреш Ярлагадда
Сриниваса Рао Равелла
Анил Карбхари Схинде
Рамасастри Камбхампати
Правин Кумар Роаяпалли
Прадип Джаяраджан
Гопинадх Бхирапунени
Срирамахандра Мурти Патнала
Йотхсна Равула
Венкатесварлу Джасти
Original Assignee
Сувен Лайф Сайенсиз Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сувен Лайф Сайенсиз Лимитед filed Critical Сувен Лайф Сайенсиз Лимитед
Publication of EA201391056A1 publication Critical patent/EA201391056A1/ru
Publication of EA022374B1 publication Critical patent/EA022374B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Изобретение относится к новым соединениям формулы (I) и их фармацевтически приемлемым солям и к композициям, содержащим их.Изобретение относится также к способу получения указанных выше соединений и их фармацевтически приемлемых солей. Соединения формулы (I) полезны при лечении различных расстройств, которые связаны с 5-НТрецепторами.
EA201391056A 2011-09-19 2012-01-05 Гетероарильные соединения в качестве лигандов 5-htрецептора EA022374B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3203CH2011 2011-09-19
PCT/IN2012/000011 WO2013042135A1 (en) 2011-09-19 2012-01-05 Heteroaryl compounds as 5-ht4 receptor ligands

Publications (2)

Publication Number Publication Date
EA201391056A1 true EA201391056A1 (ru) 2013-12-30
EA022374B1 EA022374B1 (ru) 2015-12-30

Family

ID=46001349

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391056A EA022374B1 (ru) 2011-09-19 2012-01-05 Гетероарильные соединения в качестве лигандов 5-htрецептора

Country Status (26)

Country Link
US (2) US9079894B2 (ru)
EP (1) EP2758394B1 (ru)
JP (1) JP5714729B2 (ru)
KR (1) KR101551481B1 (ru)
CN (1) CN103380131B (ru)
AP (1) AP3307A (ru)
AU (1) AU2012311057B2 (ru)
BR (1) BR112014001083B8 (ru)
CA (1) CA2823548C (ru)
CY (1) CY1116173T1 (ru)
DK (1) DK2758394T3 (ru)
EA (1) EA022374B1 (ru)
ES (1) ES2531885T3 (ru)
HK (1) HK1187340A1 (ru)
HR (1) HRP20150229T1 (ru)
IL (1) IL231305A0 (ru)
ME (1) ME02107B (ru)
MX (1) MX337721B (ru)
PL (1) PL2758394T3 (ru)
PT (1) PT2758394E (ru)
RS (1) RS53940B1 (ru)
SG (1) SG2014003560A (ru)
SI (1) SI2758394T1 (ru)
SM (1) SMT201500087B (ru)
WO (1) WO2013042135A1 (ru)
ZA (1) ZA201309100B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140041519A (ko) * 2011-06-07 2014-04-04 다이닛본 스미토모 세이야꾸 가부시끼가이샤 인다졸-유도체 및 피롤로피리딘-유도체 및 그의 약제학적 용도
JP2016523813A (ja) * 2013-04-05 2016-08-12 エービーシー バイオサイエンス エーエス 医学的使用、特に酸化ストレスまたは炎症に関連する疾患の治療、および臓器の保存または洗浄のための、バレッチンおよびその誘導体
CA2932428C (en) * 2013-12-16 2017-10-24 Suven Life Sciences Limited Indazole compounds as 5-ht4 receptor agonists
PT3180333T (pt) * 2014-08-16 2020-09-17 Suven Life Sciences Ltd Processo de produção em larga escala de oxalato de 1-isopropil-3-{5-[1-(3-metoxipropil)piperidin-4-il]-[1,3,4]oxadiazol-2-il}-1h-indazol
ES2734734T3 (es) * 2015-02-13 2019-12-11 Suven Life Sciences Ltd Compuestos de amida como agonistas del receptor 5-HT4
CN107540568A (zh) * 2017-08-25 2018-01-05 许昌恒生制药有限公司 一种乙氧酰胺苯甲酯的制备方法
MA53918A (fr) * 2018-10-18 2022-01-26 Suven Life Sciences Ltd Nouvelles utilisations d'un agoniste du récepteur 5-ht4
KR20220034739A (ko) 2019-05-31 2022-03-18 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
CN110746450A (zh) * 2019-09-17 2020-02-04 济南康和医药科技有限公司 一种贝前列素钠关键中间体的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492919A (en) * 1991-08-03 1996-02-20 Smithkline Beecham P.L.C. 5-HT4 receptor antagonists
TW360653B (en) * 1995-03-01 1999-06-11 Janssen Pharmaceutica Nv A oxadiazole compound having colon motility stimulating properties, its preparation process and its pharmaceutical composition
SI0863897T1 (en) * 1995-11-09 1999-10-31 Sanofi - Synthelabo 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht4- or h3-receptor ligands
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
BRPI0416813A (pt) 2003-11-24 2007-03-06 Pfizer compostos de ácido quinolonacarboxìlico com atividade agonista do receptor 5-ht4
BRPI0607456A2 (pt) * 2005-02-22 2009-09-08 Pfizer derivados de oxindol como agonistas do receptor 5ht4
JP4970290B2 (ja) 2005-02-25 2012-07-04 ファイザー株式会社 ベンズイソキサゾール誘導体
US7906532B2 (en) 2005-07-22 2011-03-15 Pfizer Inc. Indazole derivatives
BRPI0620146A2 (pt) * 2005-12-23 2011-11-01 Hoffmann La Roche derivados de aril-isoxazolo-4-il-oxadiazol, processo para a preparação dos referidos derivados, medicamento que os contém e usos de um desses derivados
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US20080255203A1 (en) * 2007-04-12 2008-10-16 Abbott Laboratories Heterocyclic compounds and their methods of use
JP5656880B2 (ja) * 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール

Also Published As

Publication number Publication date
BR112014001083B8 (pt) 2022-06-14
SG2014003560A (en) 2014-11-27
JP2014509320A (ja) 2014-04-17
HRP20150229T1 (hr) 2015-04-10
US9079894B2 (en) 2015-07-14
BR112014001083B1 (pt) 2022-02-01
WO2013042135A8 (en) 2013-08-15
AU2012311057B2 (en) 2015-09-17
KR20130109228A (ko) 2013-10-07
HK1187340A1 (zh) 2014-04-04
CA2823548C (en) 2015-10-27
MX2013014577A (es) 2014-03-31
AP3307A (en) 2015-06-30
ZA201309100B (en) 2014-08-27
PL2758394T3 (pl) 2015-08-31
DK2758394T3 (en) 2015-04-20
PT2758394E (pt) 2015-04-22
EP2758394B1 (en) 2015-02-18
ES2531885T3 (es) 2015-03-20
US9636335B2 (en) 2017-05-02
WO2013042135A1 (en) 2013-03-28
NZ619776A (en) 2015-04-24
SMT201500087B (it) 2015-05-05
BR112014001083A2 (pt) 2019-10-01
US20140187581A1 (en) 2014-07-03
CY1116173T1 (el) 2017-02-08
EP2758394A1 (en) 2014-07-30
CN103380131A (zh) 2013-10-30
BR112014001083A8 (pt) 2021-08-24
JP5714729B2 (ja) 2015-05-07
US20150283125A1 (en) 2015-10-08
CN103380131B (zh) 2015-12-02
AU2012311057A1 (en) 2013-08-01
KR101551481B1 (ko) 2015-09-08
SI2758394T1 (sl) 2015-05-29
AP2013007301A0 (en) 2013-12-31
ME02107B (me) 2015-10-20
MX337721B (es) 2016-03-16
EA022374B1 (ru) 2015-12-30
CA2823548A1 (en) 2013-03-28
IL231305A0 (en) 2014-04-30
RS53940B1 (en) 2015-08-31

Similar Documents

Publication Publication Date Title
EA201391056A1 (ru) Гетероарильные соединения в качестве лигандов 5-htрецептора
EA201390381A1 (ru) Триазиноксадиазолы
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
EA201492092A1 (ru) Соединения и композиции для ингибирования активности abl1, abl2 и bcr-abl1
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201490320A1 (ru) Соединения тетрагидропиридопиридина и тетрагидропиридопиримидина и их применение в качестве модуляторов рецептора c5a
EA201590879A1 (ru) Арилконденсированные и гетероарилконденсированные лактамы
EA202190619A1 (ru) Противовирусные соединения
EA201491149A1 (ru) Пиразолопиридиновые производные, способы их получения и их терапевтическое применение
EA201491623A1 (ru) Замещенные пирролидин-2-карбоксамиды
EA201391211A1 (ru) Новые соединения в качестве лигандов гистаминовых h-рецепторов
EA201490474A1 (ru) Аминохиназолины в качестве ингибиторов киназ
EA201301181A1 (ru) Триазолопиридины
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
EA201491028A8 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
EA201590735A1 (ru) 2-фенил-5-гетероциклил-тетрагидро-2h-пиран-3-аминовые соединения для применения в лечении диабета и связанных с ним расстройств
EA201490846A1 (ru) Новые производные арилхинолина
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
EA201391797A1 (ru) 3-спироциклические пиперидиновые производные в качестве агонистов грелиновых рецепторов
EA201400064A1 (ru) Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
EA201690755A1 (ru) Солевые и кристаллические формы ингибитора plk-4